Press Releases
AtriCure Announces the Launch of the cryoXT™ Device for Post-Operative Pain Management Following Amputation
September 09, 2025
New device expands AtriCure’s market opportunity in post-operative pain management while addressing a significant unmet clinical need MASON, Ohio --(BUSINESS WIRE)--Sep. 9, 2025-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation...
AtriCure to Participate in the 2025 Wells Fargo Healthcare Conference
August 20, 2025
MASON, Ohio --(BUSINESS WIRE)--Aug. 20, 2025-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating...
AtriCure Reports Second Quarter 2025 Financial Results; Raises Financial Outlook for 2025
July 29, 2025
Worldwide revenue of $136.1 million – an increase of 17.1% year over year (16.5% constant currency) Net loss of $6.2 million – an improvement of $1.8 million year over year Adjusted EBITDA of $15.4 million – an increase of $7.6 million year over year Generated $17.9 million of cash in the quarter...
AtriCure to Participate in the Canaccord Genuity 45th Annual Growth Conference
July 28, 2025
MASON, Ohio --(BUSINESS WIRE)--Jul. 28, 2025-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating...
AtriCure Completes Enrollment in LeAAPS Clinical Trial for Stroke Prevention
July 15, 2025
Largest cardiac surgery device trial ever with 6,500 patients enrolled, this landmark trial evaluates the stroke reduction benefit with AtriClip devices for the over one million cardiac surgery patients globally without a preoperative Afib diagnosis MASON, Ohio --(BUSINESS WIRE)--Jul....
AtriCure to Announce Second Quarter 2025 Financial Results
July 08, 2025
MASON, Ohio --(BUSINESS WIRE)--Jul. 8, 2025-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its second quarter...
AtriCure to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
May 23, 2025
MASON, Ohio --(BUSINESS WIRE)--May 23, 2025-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating...
AtriCure Reports First Quarter 2025 Financial Results
April 29, 2025
Worldwide revenue of $123.6 million – an increase of 13.6% year over year (14.1% constant currency) Net loss of $6.7 million – an improvement of $6.5 million year over year Adjusted EBITDA of $8.8 million – an increase of $6.0 million year over year MASON, Ohio --(BUSINESS WIRE)--Apr....
AtriCure Announces First Use of the AtriClip PRO-Mini® Device
April 10, 2025
MASON, Ohio --(BUSINESS WIRE)--Apr. 10, 2025-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced the first use of the newest AtriClip ®...
AtriCure to Announce First Quarter 2025 Financial Results
April 08, 2025
MASON, Ohio --(BUSINESS WIRE)--Apr. 8, 2025-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its first quarter...